Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Siliq

- PMLiVE

Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility

The biologics manufacturing site is expected to create more than 300 highly skilled jobs

- PMLiVE

Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test

If approved, the test could streamline the journey to diagnosis for more patients

- PMLiVE

Novo Nordisk to cut US insulin prices by up to 75% in January 2024

The decision comes just weeks after Eli Lilly announced a similar series of price cuts

- PMLiVE

Eli Lilly/Boehringer’s Jardiance for children with type 2 diabetes accepted by FDA

The incidence of type 2 diabetes in children has nearly doubled over the past two decades

- PMLiVE

Eli Lilly’s Verzenio label expanded by FDA for early breast cancer patients

The decision removes the previous 20% Ki-67 score requirement for patient selection

- PMLiVE

Eli Lilly signs agreement worth up to $600m for Confo Therapeutics’ non-opioid pain candidate

Neuropathic pain results from conditions including multiple sclerosis, diabetes, shingles or cancer

- PMLiVE

Eli Lilly announces 70% cut to US insulin prices while also capping out-of-pocket costs

Insulin manufacturers have come under fire recently over the cost of their insulin products

- PMLiVE

Paris Court of Appeal overturns Novartis and Roche’s €444m anti-competitiveness fine

It was questioned whether the companies had used their market power to boost sales of their eye disease drug

- PMLiVE

Novartis’ Cosentyx shows continued improvement in hidradenitis suppurativa patients

An estimated one in 100 people globally are affected by the inflammatory skin disease

- PMLiVE

Eli Lilly announces $450m investment in US manufacturing site

In December 2022 increased demand resulted in a short supply of two of its diabetes drugs

- PMLiVE

Eli Lilly’s Alzheimer’s drug denied FDA accelerated approval

The FDA said there was not enough trial data from patients who were treated for at least a year

- PMLiVE

AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement

Both companies will now come under the scheme imposed by the government through law

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links